Concepta PLC Result of AGM (0819I)
June 14 2017 - 7:00AM
UK Regulatory
TIDMCPT
RNS Number : 0819I
Concepta PLC
14 June 2017
14 June 2017
Concepta plc
("Concepta" or the "Company")
Result of AGM
Concepta plc (AIM:CPT), the pioneering UK healthcare company and
developer of a proprietary platform and suite of products targeted
at the personalised mobile health market with a primary focus on
women's fertility and specifically unexplained infertility*,
announces that at the Annual General Meeting held earlier today,
all proposed resolutions were passed.
Enquiries:
Concepta plc
Adam Reynolds, Chairman
Tel: +44 (0) 7785 908158
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
Beaufort Securities Limited (Broker)
Jon Belliss
Tel: +44 (0)20 7382 8300
Yellow Jersey PR Limited (Financial PR)
Felicity Winkles / Joe Burgess
Tel: +44 (0) 7748 843 871
About Concepta Plc:
Concepta plc is a pioneering UK healthcare company that has
developed a proprietary platform and products targeted at the
personalised mobile health market with a primary focus on women's
fertility and specifically unexplained infertility*.
Founded in 2013, Concepta has developed a revolutionary flagship
product 'myLotus' for home self-testing that helps women with
unexplained infertility to conceive.
myLotus is the only consumer product which allows both
quantitative and qualitative measurements of a woman's personal hCG
and LH hormone levels in an easy to use home test to facilitate
higher conception rates and early diagnosis of any fertility
problems. Competitor products currently only allow qualitative
measurement and are based on the 'average woman'.
Concepta has a defined route to market for its new 'myLotus'
product with Regulatory approvals for launch in China in place for
H1 2017 and CE-Marking for UK and Europe to follow later in 2017.
The revenue potential of the Chinese and EU infertility market is
worth c.GBP600m per annum for the company.
*Unexplained infertility refers to women that have been unable
to conceive after 6 months of trying. This highly motivated target
group of consumers won't typically be offered medical intervention
until 12 months of unsuccessfully trying, with IVF not offered
until two years. Research indicates couples start to take positive
action ahead of this time and there is little medical support to
help them do so.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGBZLFFDQFEBBX
(END) Dow Jones Newswires
June 14, 2017 07:00 ET (11:00 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024